The Supreme Court has given its consent to the UK’s BioIndustry Association (BIA) to intervene in a case that the latter says “could have far-reaching impacts on the life sciences sector”.
Read More
The government has asked drug manufacturers to increase stockpiles of medicines to ensure continued supply in the event that the UK leaves the EU in a ‘no-deal’ scenario.
Read More
Pharmaceutical industry representatives have applauded the decision to progress Brexit negotiations to the next phase, with the UK and EU having agreed the terms of the transition period.
Read More
“Urgent action” is required to boost the productivity of the UK’s R&D model, which is grappling with “unprecedented pressure”, claims a new report by Medicines Discovery Catapult and the BioIndustry Association.
Read More
Amsterdam has been named as the new home of the European Medicines Agency, triggering the start of an “ambitious” relocation programme that must be completed within 16 months.
Read More
The Medicines Manufacturing Industry Partnership (MMIP) is requesting government funds to help set up four new Centres of Excellence for medicines manufacturing across the UK, in line with wider plans to build on the exporting strengths of the country’s biopharma sector.
Read More
The pharma industry and patient groups are warning of significant delays in accessing innovative medicines on the NHS after a new budget impact threshold was waved through by health officials.
Read More
The British Medical Association says the government has failed to address the funding crisis in the NHS with the budget, offering “little meaningful financial assistance” for the service which, it warns, is now “stretched to breaking point”.
Read More
Life sciences leaders have welcomed the government’s new industrial strategy, which gives science and innovation a prominent role in plans for post-Brexit Britain.
Read More
The Association of the British Pharmaceutical Industry has described new proposals for evaluating medicines for NHS use as “heavy handed” and “unrealistic”.
Read More
The BioIndustry Association is warning that proposals to change to the way medicines and other health technologies are evaluated for NHS use could actually stop the flow of new therapies reaching patients with very rare and complex diseases.
Read More
The UK’s life sciences industry has welcomed aspects of chancellor Philip Hammond’s first Autumn statement and the government’s commitment to creating an industrial strategy which supports science and innovation, to help the sector retain its standing on the global stage following Brexit.
Read More
